Chinese Journal of Tissue Engineering Research ›› 2011, Vol. 15 ›› Issue (27): 5123-5126.doi: 10.3969/j.issn.1673-8225.2011.27.042

Previous Articles     Next Articles

HLA-identical sibling allogeneic peripheral blood stem cell transplantation in the treatment of acute leukemia

Chen Bo, Wang Zhi-guo, Zhang Hao, Xiao Liang, Fan Yan-ling, Xia Guo-qiang, Qiu Lin, Zhan Zhao-min, Zhang Bo-long, Ma Jun   

  1. Department of Hematology, Harbin Institute of Hematology & Oncology, Harbin  150010, Heilongjiang Province, China
  • Received:2011-01-26 Revised:2011-03-12 Online:2011-07-02 Published:2011-07-02
  • Contact: Wang Zhi-guo, Master, Associate chief physician, Department of Hematology, Harbin Institute of Hematology & Oncology, Harbin 150010, Heilongjiang Province, China wangzhiguo91006@163.com
  • About author:Chen Bo★, Master, Attending physician, Department of Hematology, Harbin Institute of Hematology & Oncology, Harbin 150010, Heilongjiang Province, China chenbo@csco.org.cn

PDF

555

Abstract:

BACKGROUND: HLA-identical sibling allogeneic peripheral blood hematopoietic stem cell transplantation (allo-PBSCT) is an effective treatment method for acute leukemia.
OBJECTIVE: To assess the clinical efficacy and complications of HLA-identical sibling allo-PBSCT for acute leukemia.
METHODS: A total of 25 patients with acute leukemia received HLA-identical sibling allo-PBSCT. All cases included 20 cases with acute myeloid leukemia and 5 cases with acute lymphocytic leukemia. Conditioning regimen consisted of busulphan and cyclophosphamide or cyclophosphamide and total body irradiation. Mycophenolate mofetil in combination with cyclosporine and methotrexate was used to prevent graft-versus-host disease.
RESULTS AND CONCLUSION: Hematopoietic reconstitution was observed in all patients during the follow-ups of 2-80 months. The time of neutrophil count ≥0.5×109/L and platelet ≥20×109/L was at day 12.84 (ranged 10-18 days) and day 20.32 (ranges 10-37 days), respectively. The main complications included 12 cases of sepsis, 9 cytomegalovirus infections, 3 herpes zoster virus infections, 10 acute graft-versus-host disease, 11 chronic graft-versus-host disease and 4 hemorrhagic cystitis. After follow-ups, 17 patients (68%) were in disease-free survival and 8 cases died. HLA-identical sibling allo-PBSCT as a treatment for acute leukemia is safe and efficient.

CLC Number: